Other
receivables consisted of the following:
SCHEDULE OF OTHER RECEIVABLE
| | |
December
31, 2025 | | |
December
31, 2024 | |
| Loan receivable(1) | |
$ | 14,355,283 | | |
$ | — | |
| Proceeds receivable from sale of subsidiary(2) | |
| 2,416,086 | | |
| — | |
| Other | |
| 559 | | |
| 94,074 | |
| Other receivables, net | |
$ | 16,771,928 | | |
$ | 94,074 | |
| (1) | During
the year ended December 31, 2025, the Company entered into five borrowing arrangements with
a third party for an aggregate principal amount of $14,160,101, bearing interest at 9% per
annum. Certain borrowings were guaranteed by individuals or entities or secured by certain
assets. As of December 31, 2025, the aggregate accrued and unpaid interest related to these
borrowings was $195,182. |
To
date, all of the above borrowings, including the related accrued interest, had been fully repaid.
| (2) | There
was $2,416,086 receivable from the sale of the Company’s subsidiary, SYCI, which is
due in 2026 from Shandong Rongyuan Pharmaceutical Co., Ltd. |
|